BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37477781)

  • 1. Clinical presentation of MEN 2A in index vs. non-index patients.
    Machens A; Lorenz K; Weber F; Brandenburg T; Führer-Sakel D; Dralle H
    Endocrine; 2023 Nov; 82(2):450-455. PubMed ID: 37477781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families.
    Wang YP; Li FP; Wang HH; Fang XD; Zhu ZS; Chen YL; Qi XP
    Endocr Metab Immune Disord Drug Targets; 2022; 22(3):339-347. PubMed ID: 34445950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catecholamine crisis as a first manifestation of familial bilateral pheochromocytoma caused by RET proto-oncogene mutation in codon C 634R.
    Zwolak A; Rudzki G; Świrska J; Dudzińska M; Daniluk J; Tarach J
    Endokrynol Pol; 2015; 66(5):462-8. PubMed ID: 26457501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple endocrine neoplasia type 2A: case report.
    Păun DL; Poiană C; Petriş R; Radian S; Miulescu RD; Constantinescu G; Orban C
    Chirurgia (Bucur); 2013; 108(6):900-3. PubMed ID: 24331334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case.
    Hibi Y; Ohye T; Ogawa K; Shimizu Y; Shibata M; Kagawa C; Mizuno Y; Uchino S; Kosugi S; Kurahashi H; Iwase K
    Surg Today; 2014 Nov; 44(11):2195-200. PubMed ID: 24449023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Changing Face of Multiple Endocrine Neoplasia 2A: From Symptom-Based to Preventative Medicine.
    Machens A; Lorenz K; Brandenburg T; Führer-Sakel D; Weber F; Dralle H
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e734-e742. PubMed ID: 36930525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
    Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
    Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary medullary thyroid carcinoma syndromes: experience from western India.
    Diwaker C; Sarathi V; Jaiswal SK; Shah R; Deshmukh A; Thomas AE; Prakash G; Malhotra G; Patil V; Lila A; Shah N; Bandgar T
    Fam Cancer; 2021 Jul; 20(3):241-251. PubMed ID: 33392850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in MEN 2A penetrance and expression according to parental inheritance.
    Machens A; Lorenz K; Weber F; Dralle H
    Eur J Endocrinol; 2022 Feb; 186(4):469-476. PubMed ID: 35130180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China.
    Qi XP; Chen XL; Ma JM; Du ZF; Fei J; Yang CP; Cheng J; Song QZ; Han JS; Jin HY; Chen ZG; Wang JQ; Yang YP; Ying RB; Liu WT; Zhao Y; Chen CY; Jiang HL; Ke HP; Zhang XN
    Thyroid; 2012 Dec; 22(12):1257-65. PubMed ID: 23210566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A MEN2A family with two asymptomatic carriers affected by unilateral renal agenesis.
    Hibi Y; Ohye T; Ogawa K; Shimizu Y; Shibata M; Kagawa C; Mizuno Y; Kurahashi H; Iwase K
    Endocr J; 2014; 61(1):19-23. PubMed ID: 24152999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pheochromocytoma and medullary thyroid carcinoma in a pregnant multiple endocrine neoplasia-2A patient.
    Sarathi V; Bandgar TR; Menon PS; Shah NS
    Gynecol Endocrinol; 2011 Aug; 27(8):533-5. PubMed ID: 20672905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison of clinical characteristics between 2 pedigrees of multiple endocrine neoplasia type 2A with different RET mutations].
    Weng Y; Xue SN; Zhang SL; Cheng H; Yan L
    Zhonghua Nei Ke Za Zhi; 2018 Feb; 57(2):134-137. PubMed ID: 29397600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
    Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
    Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A.
    Machens A; Elwerr M; Lorenz K; Weber F; Dralle H
    Endocrine; 2020 May; 68(2):368-376. PubMed ID: 32100189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple endocrine neoplasia syndromes. Type 2].
    Juodele L; Juozaityte E; Zindzius A; Pundzius J
    Medicina (Kaunas); 2005; 41(4):281-94. PubMed ID: 15864001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of multiple endocrine neoplasia type 2A (MEN2A) with a mutation in the RET gene].
    Ishizu K; Shiraishi K; Kawamura H; Naito K; Takahashi T; Yoshimura K; Tangoku A; Shirahama S
    Hinyokika Kiyo; 1999 Jun; 45(6):407-10. PubMed ID: 10442282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple endocrine neoplasia type 2.
    Gertner ME; Kebebew E
    Curr Treat Options Oncol; 2004 Aug; 5(4):315-25. PubMed ID: 15233908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
    Machens A; Dralle H
    Curr Opin Oncol; 2024 Jan; 36(1):1-12. PubMed ID: 37975407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.